High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

INTRODUCTION: Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor) is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV + ASV is affected by DCV resistance-associated polymorphisms (RAPs) in HCV NS5A...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Adv Ther
Autori principali: McPhee, Fiona, Suzuki, Yoshiyuki, Toyota, Joji, Karino, Yoshiyasu, Chayama, Kasuaki, Kawakami, Yoshiiku, Yu, Min Lung, Ahn, Sang Hoon, Ishikawa, Hiroki, Bhore, Rafia, Zhou, Nannan, Hernandez, Dennis, Mendez, Patricia, Kumada, Hiromitsu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Healthcare 2015
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522028/
https://ncbi.nlm.nih.gov/pubmed/26155891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0221-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi